On Nov 02, major Wall Street analysts update their ratings for $Regeneron Pharmaceuticals (REGN.US)$, with price targets ranging from $800 to $1,195.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and maintains the target price at $1,184.
BofA Securities analyst Alec Stranahan maintains with a sell rating, and adjusts the target price from $805 to $800.
Barclays analyst Carter Gould maintains with a buy rating, and adjusts the target price from $1,080 to $1,065.
UBS analyst Colin Bristow maintains with a buy rating, and adjusts the target price from $1,251 to $1,130.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $1,170.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
Regeneron's Q3 financial results surpassed expectations marginally in terms of revenue and more significantly in earnings per share. Nevertheless, this was eclipsed by the performance of the Eylea franchise. Concerns have been raised about the future of the Eylea franchise due to the impending introduction of a biosimilar version by a competitor. These concerns encompass not only the anticipated faster erosion of the standard dose's market share, which may be underestimated by the market, but also potential negative effects on the higher dose variant.
Recent pressures on Regeneron shares are seen as excessive, according to analysts. This sentiment follows reactions to developments with Pavblu and a less than favorable Q4 outlook for Eylea HD, coupled with unclear projections regarding Eylea's future growth.
The decline in Regeneron's stock value following Q3 earnings was somewhat unexpected, as it was presumed that the near- and long-term consensus estimates for the optho franchise were overly optimistic. Nevertheless, it is believed that Regeneron's intrinsic fair value is substantially higher than the current share price.
Regeneron's recent quarterly financials aligned with optimistic revenue projections and surpassed expectations on earnings growth. However, the company's stock continues to encounter challenges stemming from its Eylea franchise and the looming threat of biosimilar competitors. The anticipated impact of a biosimilar by a competing company is still uncertain, but the initial response suggests it may not be as significant as feared, particularly given the tepid reception of other similar biosimilars in the market. The market's reaction to the pace at which patients are transitioning to Eylea HD has further pressured the stock's performance.
Here are the latest investment ratings and price targets for $Regeneron Pharmaceuticals (REGN.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月2日，多家華爾街大行更新了$再生元製藥公司 (REGN.US)$的評級，目標價介於800美元至1,195美元。
摩根士丹利分析師Terence Flynn維持買入評級，維持目標價1,184美元。
美銀證券分析師Alec Stranahan維持賣出評級，並將目標價從805美元下調至800美元。
巴克萊銀行分析師Carter Gould維持買入評級，並將目標價從1,080美元下調至1,065美元。
瑞士銀行分析師Colin Bristow維持買入評級，並將目標價從1,251美元下調至1,130美元。
Evercore分析師Cory Kasimov維持買入評級，維持目標價1,170美元。
此外，綜合報道，$再生元製藥公司 (REGN.US)$近期主要分析師觀點如下：
雷基諾（Regeneron）第三季度的財務業績在營業收入方面略高於預期，盈利每股表現更有顯著。然而，埃勒亞（Eylea）系列的表現卻讓這些黯然失色。人們對埃勒亞系列的未來提出了擔憂，原因是一家競爭對手即將推出生物類似藥的版本。這些擔憂不僅涵蓋了標準劑量市場份額預計的更快侵蝕可能被市場低估的問題，還包括對較高劑量變種可能產生的負面影響。
根據分析師的看法，近期雷基諾公司股票的壓力被認爲是過度的。這一觀點是對Pavblu和埃勒亞 HD 不太樂觀的第四季度前景所作出的反應，再加上對埃勒亞未來增長前景的不明確預測。
雷基諾公司在第三季度業績後股價下跌的情況略有出乎意料，因爲管眼科系列的近期和長期共識預估被認爲過於樂觀。然而，有人認爲雷基諾公司的內在公平價值遠遠高於當前股價。
雷基諾最近的季度財務狀況符合樂觀的營業收入預測，並在盈利增長方面超出預期。然而，由於埃勒亞系列的挑戰以及生物類似藥競爭對手的潛在威脅，公司股票繼續面臨挑戰。競爭公司推出的生物類似藥的預期影響仍未確定，但初步反應表明可能不及原先擔憂的那麼重大，尤其考慮到市場上其他類似生物類似藥的受冷淡的接受程度。市場對患者過渡到埃勒亞 HD 的速度做出的反應進一步加大了股價的壓力。
以下爲今日9位分析師對$再生元製藥公司 (REGN.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
